The startup specializes in designing potent ligand traps through protein engineering and an in-depth understanding of transforming growth factor-beta structure-function relationships, targeting pulmonary hypertension and musculoskeletal disorders. This approach enables the development of biologics that effectively address the unmet medical needs of patients suffering from these conditions.

ALENTIS Therapeutics develops anti-Claudin-1 monoclonal antibodies and antibody-drug conjugates to treat cancer and reverse fibrosis by targeting Claudin-1 to disrupt disease signaling and selectively kill tumor cells. Their clinical pipeline includes candidates for solid tumors and organ fibrosis, addressing significant unmet medical needs in advanced liver disease and various cancers.

The startup develops small molecule therapies that target synthetic lethal metabolic dependencies in cancer by disrupting stress response pathways essential for cancer cell survival. This approach enables patients to inhibit specific pathways that contribute to cancer cell growth, potentially improving treatment outcomes.

Alpha9 Theranostics develops peptide-based radiopharmaceuticals for the targeted treatment of solid and hematologic malignancies. Their technology aims to improve therapeutic precision and efficacy, addressing the limitations of conventional cancer therapies.

Aspen Neuroscience develops autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy specifically for Parkinson's disease, utilizing advanced stem cell biology and genomics. This approach addresses the degeneration of neurons in patients, aiming to restore lost function and improve quality of life.

Atopia Therapeutics is developing ATP-R13, a recombinant protein derived from *Helicobacter pylori*, to modulate the immune response and reduce inflammation in patients with asthma, eczema, and food allergies. This first-in-class therapy aims to address the rising prevalence of allergic diseases affecting billions globally by re-establishing immune tolerance and alleviating symptoms.

Bluejay Therapeutics is developing monoclonal antibodies targeting chronic viral infections, specifically focusing on chronic hepatitis D and B. The company aims to provide effective treatment options that achieve high virologic response rates, addressing the unmet need for cures in infectious liver diseases.

Callio provides a cloud‑hosted platform that lets robotics competition organizers define scoring rules, schedule matches, and monitor live telemetry from robot controllers via MQTT, ROS2, and other protocols. The web‑based challenge screen offers real‑time dashboards, role‑based access, and persistent result storage with export APIs for LMS and analytics. It integrates with existing hardware simulators and learning management systems through REST and WebSocket interfaces.

Cirius Therapeutics is a clinical-stage pharmaceutical company developing azemiglitazone, an insulin sensitizer aimed at treating non-alcoholic steatohepatitis and other diseases linked to insulin resistance, such as Type 2 Diabetes and metabolic dysfunctions associated with obesity. Their approach targets the underlying metabolic disturbances, potentially improving liver health and metabolic outcomes for affected patients.

Diagonal Therapeutics utilizes a proprietary platform that combines computational and experimental techniques to rapidly identify and produce agonist antibodies that activate specific receptor complexes. This approach addresses the challenge of developing therapies for debilitating diseases by reactivating critical biological pathways, offering potential treatments for conditions like hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Develops first-in-class covalent protein therapeutics using a proprietary synthetic biology platform that incorporates unnatural amino acids to create irreversibly binding "War-Lock" biologics. This approach improves target modulation, reduces off-target effects, and enables sustained therapeutic efficacy with minimal systemic exposure, addressing limitations of traditional protein drugs in treating cancer and other serious diseases.

Eyconis uses the TransCon prodrug platform to create long‑acting, sustained‑release formulations of ophthalmic medicines, enabling controlled drug delivery inside the eye for months to years. By covalently linking active agents to a biodegradable carrier, the company aims to reduce the frequency of intravitreal injections for retinal diseases such as wet AMD, diabetic macular edema, retinal vein occlusion, and geographic atrophy, improving patient adherence and visual outcomes.

The startup is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for patients with genetic diseases through advanced biological research. By creating medicines that address significant unmet medical needs, the company aims to improve treatment outcomes for rare genetic conditions across various therapeutic areas and stages of development.

Develops RIPTAC™ therapeutics, a novel class of precision cancer treatments that use a protein-protein interaction mechanism to selectively bind tumor-specific proteins and essential cellular functions, leading to targeted cancer cell death. This approach addresses the limitations of traditional therapies by offering a more precise and effective method for treating major solid tumors.

Hillstar Bio develops precision immunotherapies that selectively deplete pathogenic immune‑cell subsets to reset the immune system in autoimmune diseases. By engineering antibodies that target disease‑specific genetic markers, its candidates aim to spare healthy cells, reduce adverse effects, and enable less frequent dosing compared to broad immunosuppression. The lead program, HSB‑101, targets TRBV9+ T cells for axial spondyloarthritis and related HLA‑B27‑mediated conditions, with preclinical work advancing toward a Phase 1 trial.

Hummingbird Bioscience develops next-generation antibody-drug conjugates (ADCs) using proprietary linker-payload technologies to target cancer cells with high specificity. Their approach aims to provide effective treatment options for patients who do not respond to existing therapies, enhancing the potential for durable clinical responses.

Inipharm is a biopharmaceutical company developing small-molecule inhibitors targeting the HSD17B13 protein to treat severe liver diseases, including nonalcoholic steatohepatitis (NASH) and fibrosis. Their approach leverages genetic insights that link HSD17B13 variants to reduced liver disease severity, aiming to improve liver health outcomes through anti-fibrotic therapies.

This clinical-stage company develops targeted formulations for the treatment of ocular inflammation, utilizing a platform that integrates immunology and ophthalmology for precise tissue delivery. By addressing inflammation at its source in both the anterior and posterior segments of the eye, the company enhances treatment efficacy and safety for patients with ocular diseases.

Lassen Therapeutics develops fully human monoclonal antibodies targeting the interleukin-11 receptor to treat fibrotic diseases such as thyroid eye disease and idiopathic pulmonary fibrosis. Their approach aims to inhibit IL-11 signaling, addressing the underlying mechanisms of fibrosis to improve patient outcomes.

Maze Therapeutics develops precision medicines by leveraging human genetics to target the underlying drivers of common diseases with significant unmet needs. The company utilizes its Compass platform for variant functionalization to design therapeutics that mimic protective genetic variants. Its current pipeline focuses on developing treatments for chronic kidney disease, including APOL1-mediated kidney disease.

MBX Biosciences develops precision endocrine peptides (PEPs) to treat rare endocrine and metabolic disorders, focusing on unmet medical needs in underserved patient populations. Their therapies aim to improve disease management and enhance the quality of life for individuals living with complex endocrine conditions.

Radionetics Oncology develops small molecule radiopharmaceuticals that target G protein-coupled receptors (GPCRs) to deliver therapeutic radioisotopes directly to solid tumors, enhancing treatment precision. This approach addresses the need for effective cancer therapies by enabling targeted radiation delivery while minimizing damage to surrounding healthy tissue.

Scorpion Therapeutics develops precision oncology therapies that target specific genetic mutations and chromosomal instabilities in cancer cells, enhancing treatment efficacy and safety. By focusing on validated cancer drivers, the company aims to increase the eligibility and clinical benefit of precision therapies for a broader population of cancer patients.

Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases caused by immune system imbalances. By utilizing proprietary platform technologies, the company aims to induce durable immune tolerance, providing a potential cure for patients suffering from these conditions.